Pluri Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Pluri Inc. (PLUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.13 per share for the 6-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-12
- Pluri Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $4.89, a 5.96% decline year-over-year.
- Pluri Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-09-30 was $5.20.
- Pluri Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Pluri Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $3.85.
- Pluri Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.87, a 70.59% decline from fiscal 2021.
- Pluri Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $9.76, a 167.40% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $2.13 10-Q · filed 2026-02-12 | ||||
| 2025-09-30 | $4.89 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $0.00 10-K · filed 2025-09-17 | ||||
| 2025-03-31 | $4.46 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | $0.00 10-Q · filed 2026-02-12 | $5.20 10-Q · filed 2025-02-11 | |||
| 2024-09-30 | $5.20 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | $3.85 10-K · filed 2025-09-17 | ||||
| 2022-06-30 | $2.87 10-K · filed 2022-09-21 | ||||
| 2021-06-30 | $9.76 10-K · filed 2022-09-21 | ||||
| 2020-06-30 | $3.65 10-K · filed 2021-09-13 | ||||
| 2019-06-30 | $8.70 10-K · filed 2020-09-10 | ||||
| 2018-06-30 | $14.00 10-K · filed 2020-09-10 | ||||
| 2017-06-30 | $14.10 10-K · filed 2019-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |